Table 2 Trends by waves in GN/GP pathogens and antibiotic therapy for pre- and post-SARS-CoV-2 periods by SARS-CoV-2 testing status
Time period | SARS-CoV-2 + | SARS-CoV-2 − | SARS-CoV-2 not tested | Total admissions | ||||
|---|---|---|---|---|---|---|---|---|
Prescribed antibacterial therapy ≥ 24 h | Positive GN/GP culture during hospital stay | Prescribed antibacterial therapy ≥ 24 h | Positive GN/GP culture during hospital stay | Prescribed antibacterial therapy ≥ 24 h | Positive GN/GP culture during hospital stay | Prescribed antibacterial therapy ≥ 24 h | Positive GN/GP culture during hospital stay | |
Total: Jul 2019–Oct 2021 | 57.8%* (109,337/189,115) | 11.9%* (22,558/ 189,115) | 40.1% (761,398/ 1,898,659) | 11.0%* (208,162/ 1,898,659) | 32.8% (1,124,606/3,430,970) | 8.3%* (285,279/ 3,430,970) | 36.2% (1,995,381/ 5,518,744) | 9.3% (515,999/ 5,518,744) |
Baseline: Jul 2019–Feb 2020 | 35.0% (625,994/1,789,449) | 9.3% (167,045/ 1,789,449) | 35.0% (625,994/ 1,789,449) | 9.3% (167,045/ 1,789,449) | ||||
Total: Mar 2020–Oct 2021 | 57.8% (109,337/189,115) | 11.9% (22,558/ 189,115) | 40.1% (761,398/ 1,898,659) | 11.0% (208,162/ 1,898,659) | 30.4% (498,612/ 1,641,521) | 7.2% (118,234/ 1,641,521) | 36.7% (1,369,387/ 2,359,908) | 9.4% (348,954/ 3,729,295) |
Mar 2020–May 2020 | 67.8% (10,643/15,702) | 13.2% (2,067/ 15,702) | 46.8% (54,681/ 116,755) | 12.5% (14,541/ 116,755) | 33.3% (132,120/396,348) | 8.7% (34,422/396,348) | 37.3% (197,444/528,805) | 9.7% (51,030/ 528,805) |
Jun 2020–Aug 2020 | 63.2% (16,862/26,699) | 12.9% (3,443/ 26,699) | 40.2% (130,724/ 324,814) | 11.2% (36,312/ 324,814) | 27.9% (73,288/262,947) | 6.7% (17,740/262,947) | 35.9% (220,874/614,460) | 9.4% (57,495/ 614,460) |
Sep 2020–Nov 2020 | 57.6% (15,025/26,081) | 11.5% (2,995/ 26,081) | 40.0% (135,412/ 338,745) | 11.0% (37,135/ 338,745) | 30.3% (70,141/231,131) | 7.0% (16,225/231,131) | 37.0% (220,578/595,957) | 9.5% (56,355/ 595,957) |
Dec 2020–Feb 2021 | 57.2% (33,076/57,819) | 11.9% (6,873/ 57,819) | 39.4% (126,140/ 319,865) | 10.7% (34,346/ 319,865) | 30.8% (57,306/186,155) | 6.6% (12,194/186,155) | 38.4% (216,522/563,839) | 9.5% (53,413/ 563,839) |
Mar 2021–May 2021 | 54.4% (10,686/19,645) | 12.2% (2,392/ 19,645) | 39.5% (139,349/ 353,050) | 10.6% (37,445/ 353,050) | 28.9% (66,789/231,491) | 6.6% (15,191/231,491) | 35.9% (216,824/604,186) | 9.1% (55,028/ 604,186) |
Jun 2021–Oct 2021 | 53.5% (23,085/43,169) | 11.1% (4,788/ 43,169) | 39.3% (175,092/ 445,430) | 10.9% (48,383/ 445,430) | 29.7% (98,968/333,449) | 6.7% (22,462/333,449) | 36.1% (297,145/822,048) | 9.2% (75,633/ 822,048) |